4-(4-甲氧基苯基)-2,4-二氧丁酸 | 55558-77-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-(4-甲氧基苯基)-2,4-二氧丁酸
• 英文名称: p-methoxybenzoyl pyruvic acid
• 英文别名: 4-(4-Methoxyphenyl)-2,4-dioxobutanoic acid
• CAS: 55558-77-5
• 化学式: C₁₁H₁₀O₅
• 分子量: 222.197
• InChiKey: QTDIUFUNHQSHTP-UHFFFAOYSA-N

物化性质

• 沸点：
  417.8±25.0 °C(Predicted)
• 密度：
  1.309±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  80.7
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  4-(4-甲氧基苯基)-2,4-二氧丁酸 在 一水合肼 、 溶剂黄146 作用下， 以92%的产率得到5-(4-甲氧基苯基)-1H-吡唑-3-羧酸
  参考文献：
  名称：

  5-Aryl-1H-pyrazole-3-carboxylic acids as selective inhibitors of human carbonic anhydrases IX and XII

  摘要：

  Inhibitory activity of a congeneric set of 23 phenyl-substituted 5-phenyl-pyrazole-3-carboxylic acids toward human carbonic anhydrase (hCA, EC 4.2.1.1) isoforms I, II, IX and XII was evaluated by a stopped-flow CO2 hydrase assay. These compounds exerted a clear, selective inhibition of hCA IX and XII over hCAI and II, with Ki in two to one digit micromolar concentrations (4-50 mu M). Derivatives bearing bulkier substituents in para-position of the phenyl ring inhibited hCA XII at one-digit micromolar concentrations, while derivatives having alkyl substituents in both ortho-and meta-positions inhibited hCA IX with Kis ranging between 5 and 25 mu M. Results of docking experiments offered a rational explanation on the selectivity of these compounds toward CA IX and XII, as well as on the substitution patterns leading to best CA IX or CA XII inhibitors. By examining the active sites of these four isoforms with GRID generated molecular-interaction fields, striking differences between hCA XII and the other three isoforms were observed. The field of hydrophobic probe (DRY) appeared significantly different in CA XII active site, comparing to other three isoforms studied. To the best of our knowledge such an observation was not reported in literature so far. Considering the selectivity of these carboxylates towards membrane-associated over cytosolic CA isoforms, the title compounds could be useful for the development of isoform-specific non-sulfonamide CA inhibitors. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.05.052
• 作为产物：
  描述：

  对甲氧基苯乙酮 在 lithium hydroxide monohydrate 、 sodium hydride 作用下， 以 四氢呋喃 、 甲醇 、 水 、 甲苯 为溶剂， 反应 0.5h， 生成 4-(4-甲氧基苯基)-2,4-二氧丁酸
  参考文献：
  名称：

  非肽类新型血小板聚集抑制剂：设计、合成、生物评价、SAR 和计算机研究

  摘要：

  一系列 2-oxo-2-phenylethylidene 连接的 2-oxo-benzo[1,4]oxazine 类似物 17a-x 和 18a-o，在环 A 和环 C，在更环保的条件下以优异的产率（高达 98%）合成。与标准参考阿司匹林 (IC50 = 21.34 ± 1.09 µg/mL) 相比，评估了这些类似物 17a-x 和 18a-o 的花生四烯酸 (AA) 诱导的血小板聚集抑制活性。在所有筛选的化合物中，与阿司匹林相比，8 种类似物 17i、17x、18f、18g、18h、18i、18l 和 18o 被鉴定为有前途的血小板聚集抑制剂。此外，通过 MTT 分析对 3T3 成纤维细胞系进行了有希望的化合物（17i、17x、18f-18i、18l、和 18o) 并且发现这些化合物在性质上是无毒的。此外，这些化合物（17i、17x、18f-18i、18l 和 18o）的 AA 诱导的血

  DOI：

  10.1002/ardp.201700349

文献信息

• Synthesis of Pyrrolo[2,1-c][1,4]oxazine-1,6,7-triones by the Reaction of 3-Methylenemorpholin-2-ones with Oxalyl Chloride
  作者：N. A. Tret’yakov、M. V. Dmitriev、A. N. Maslivets

  DOI：10.1134/s1070428020080060

  日期：2020.8

  Abstract (Z)-3-(2-Aryl-2-oxoethylidene)morpholin-2-ones were synthesized by the reaction of aroylpyruvic acids with ethanolamine or 2-propanolamine. The products reacted with oxalyl chloride to form 8-aroyl-3,4-dihydropyrrolo[2,1-c][1,4]oxazin-1,6,7(1H)-triones.

  摘要 通过芳酰基丙酮酸与乙醇胺或2-丙醇胺的反应合成了（Z）-3-（2-芳基-2-氧代亚乙基）吗啉-2-酮。产物与草酰氯反应形成8-芳基-3,4-二氢吡咯并[2,1- c ] [1,4]恶嗪-1,6,7（1 H）-三酮。
• “On water” ultrasound-assisted one pot efficient synthesis of functionalized 2-oxo-benzo[1,4]oxazines: First application to the synthesis of anticancer indole alkaloid, Cephalandole A
  作者：Pradeep K. Jaiswal、Vashundhra Sharma、Jaroslav Prikhodko、Irina V. Mashevskaya、Sandeep Chaudhary

  DOI：10.1016/j.tetlet.2017.03.048

  日期：2017.5

  For the first time, an efficient, simple, synthetic green protocol for the one-pot synthesis of functionalized 2-oxo-benzo[1,4]oxazines 24–29 in water under ultrasound irradiation is presented. As compared to conventional methods, the present protocol avoids traditional chromatography and purification steps and furnished the target molecules in excellent yields (upto 98%) with no side products. The

  对于第一次，一个高效，简便的，合成的绿协议的一锅合成官能-2-氧代苯并[1,4]恶嗪24 - 29在超声照射下的水被呈现。与常规方法相比，本方案避免了传统的色谱和纯化步骤，并以极高的收率（高达98％）提供了目标分子，且没有副产物。该方法也已在克级合成中得到证明。此外，官能化2-氧代-喹喔啉类似物31 - 33，另一类生物活性杂环支架的，使用这种方法，还制备。该方案首次成功地用于抗癌吲哚生物碱Cephalandole A的合成35。
• Synthesis and Intramolecular Cyclization of Substituted 4-(Het)aryl-4-oxo-2-thienylaminobut-2-enoic Acids Containing Nitrile Group in the Thiophene Ring
  作者：I. A. Gorbunova、D. A. Shipilovskikh、A. E. Rubtsov、S. A. Shipilovskikh

  DOI：10.1134/s1070363221090048

  日期：2021.9

  A method for the synthesis of substituted 4-(het)aryl-4-oxo-2-thienylaminobut-2-enoic acids containing a nitrile substituent in the thiophene ring was proposed. Intramolecular cyclization of the obtained compounds in the presence of propionic anhydride leads to the formation of new substituted 3-thienylimino-3H-furan-2-ones.

  提出了一种合成噻吩环上含有腈取代基的取代4-(het)aryl-4-oxo-2-thienylaminobut-2-enoic酸的方法。在丙酸酐存在下，所得化合物的分子内环化导致形成新的取代的 3-噻吩基亚氨基-3H-呋喃-2-酮。
• Furan-2,3-diones as masked dipoles: synthesis of isotetronic acids and mechanistic considerations
  作者：Vincent Barbier、François Couty、Olivier R.P. David

  DOI：10.1016/j.tet.2016.07.072

  日期：2016.9

  The formal dipolar behaviour of furan-2,3-diones is illustrated by their reaction with ethyl glyoxylate under Lewis basic activation uniquely, giving access to isotetronic derivatives. The Janus-type nature of the activated species, both nucleophilic and electrophilic is revealed by ring-opening of the starting ketolactone. An unexpected reversible side-reaction was identified by in situ monitoring

  呋喃-2,3-二酮的形式偶极行为可以通过在Lewis碱性活化下与乙醛酸乙酯的反应来唯一说明，从而获得了等电子衍生物。通过起始酮内酯的开环揭示了亲核和亲电子的活化物种的Janus型性质。通过原位监测发现意外的可逆反应。
• NOVEL PYRROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
  申请人：Kai Hiroyuki

  公开号：US20100210632A1

  公开（公告）日：2010-08-19

  The present invention provides a compound represented by the formula (I): wherein R 1 , R 2 , R 3 , Z 1 , Z 2 , R a , R b , q, A and n are as defined in the description, a pharmaceutically acceptable salt or solvate thereof. The compound is useful as P2X 3 and/or P2X 2 / 3 receptor antagonist.

  本发明提供了一种由式(I)所表示的化合物：其中R1、R2、R3、Z1、Z2、Ra、Rb、q、A和n如描述中所定义，以及其药学上可接受的盐或溶剂。该化合物可用作P2X3和/或P2X2/3受体拮抗剂。